Sodium selenite inhibits the expression of VEGF, TGFβ1 and IL-6 induced by LPS in human PC3 cells via TLR4-NF-KB signaling blockage

International Immunopharmacology

Volumn 10, Issue 1, 2010, Pages 50-56

  Pei, Zengyang ^a   Li, Hui ^a   Guo, Ying ^a   Jin, Yipeng ^a   Lin, Degui ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

IL 6; Prostate tumor; Selenium; TGF 1; TLR4; VEGF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SODIUM SELENITE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNIZATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SODIUM SELENITE; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73149119781     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.09.020     Document Type: Article

References (47)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer Statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Zu K., and Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 63 (2003) 6988-6995
3. Dennis L.K., Lynch C.F., and Torner J.C. Epidemiologic association between prostatitis and prostate cancer. J Urology 60 1 (2002) 78-83
4. Kundu S.D., Lee C., Billips B.K., Habermacher G.M., Zhang Q., Liu V., et al. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68 (2008) 223-229
5. Domingue G.J., and Hellstrom W.J.G. Prostatitis. Clin Microbiol Rev 11 (1998) 604-613
6. Rippere-Lampe K.E., Lang M., Ceri H., Olson M., Lockman H.A., and Brien A.D.O. Cytotoxic necrotizing factor type 1-positive Escherichia coli causes increased inflammation and tissue damage to the prostate in a rat prostatitis model. Infect Immun 69 (2001) 6515-6519
7. Akira S., Takeda K., and Kaisho T. Toll-Like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 (2001) 675-680
8. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
9. Zheng S.L., Augustsson-Bälter K., Chang B., Hedelin M., Li L., Adami H.-O., et al. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the cancer prostate in Sweden study. Cancer Res 64 (2004) 2918-2922
10. Cheng I., Plummer S.J., Casey G., and Witte J.S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomark 16 2 (2007) 352-355
11. Kelly M.G., Alvero A.B., Chen R., Silasi D.-A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66 7 (2006) 3859-3868
12. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 16 (2006) 80-88
13. Pei Z., Lin D., Song X., Li H., and Yao H. TLR4 signaling promotes the expression of VEGF and TGFb1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol 254 1 (2008) 20-27
14. Combs G.F., and Gray W.P. Chemopreventive agents: selenium. Pharmacol Therapeut 79 3 (1998) 179-192
15. Zeng H., and Jr G F C. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19 (2008) 1-7
16. Youn H.-S., Lim H.J., Choi Y.J., Lee J.Y., Lee M.-Y., and Ryu J.-H. Selenium suppresses the activation of transcription factor NF-κB and IRF3 induced by TLR3 or TLR4 agonists. Int Immunopharmacol 8 (2008) 495-501
17. Prabhu K.S., Zamamiri-Davis F., Stewart J.B., Thompson J.T., Sordillo L.M., and Reddy C.C. Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW 264.7 macrophages: role of nuclear factor-kappaB in up regulation. Biochem J 366 (2002) 203-209
18. Yun C.-H., Yang J.S., Kang S.-S., Yang Y., Cho J.H., Son C.G., et al. NF-κB signaling pathway, not IFN-β/STAT1, is responsible for the selenium suppression of LPS-induced nitric oxide production. Int Immunopharmacol 7 (2007) 1192-1198
19. Ferguson L.R., and Philpott M. Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Tar 7 (2007) 459-464
20. KB) in prostate cancer cells. Mol Cancer Ther 1 12 (2002) 1079-1087
21. KB regulated gene expression in uninduced human prostate cancer cells. Nutr Cancer 58 2 (2007) 197-204
22. Hua D., Liu M.-Y., Cheng Z.D., Qin X.J., Zhang H.M., Chen Y., et al. Small interfering RNA-directed targeting of toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 46 (2009) 2876-2884
23. Untergassera G., Gandera R., Rumpoldb H., Heinricha E., Plasc E., and Berger P. TGF- b cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Exp Gerontol 38 (2003) 1179-1188
24. Mazzucchelli R., Montironi R., Santinelli A., Lucarini G., Pugnaloni A., and Biagini G. Vascular endothelial growth factor expressionand capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45 (2000) 72-79
25. He W., Liu Q., Wang L., Chen W., Li N., and Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44 (2007) 2850-2859
26. Kiriakidis S., Andreakos E., Monaco C., Foxwell B., Feldmann M., and Paleolog E. VEGF expression in human macrophages is NF-kB dependent: studies using adenoviruses expressing the endogenous NF-kB inhibitor IkBa and a kinasedefective form of the IkB kinase 2. J Cell Sci 116 4 (2003) 665-674
27. Chen Y., Kam C.S.K., Liu F.Q., Liu Y., Lui V.C.H., Lamb J.R., et al. LPS-induced up-regulation of TGF-β receptor 1 is associated with TNF- expression in human monocyte-derived macrophages. J Leukoc Biol 83 (2008) 1165-1173
28. KB and MAPKs signaling pathways. Mol Immunol 44 (2007) 984-992
29. Roberts R.O., Bergstralh E.J., Bass S.E., Lieber M.M., and Jacobsen S.J. Prostatitis as a risk factor for prostate cancer. Epidemiology 15 (2004) 93-99
30. El-Bayoumy K., and Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat Res 591 (2005) 224-236
31. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
32. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 (2003) 643-651
33. Guo Y., Wang S., Hoot D.R., and Clinton S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 18 (2007) 408-417
34. Takahashi A., Kono K., Ichihara F., Sugai H., Fujii H., and Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immun 53 (2004) 543-550
35. Roskoski J.R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62 (2007) 179-213
36. Bello-DeOcampo D., and Tindall D.J. TGF-ß/Smad signaling in prostate cancer. Curr Drug Targets 4 (2003) 197-207
37. Thomas D.A., and Massagué J. TGF-b directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005) 369-380
38. Li M.O., Sanjabi S., and Flavell R.A. Transforming growth factor-b controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and independent mechanisms. Immunity 25 (2006) 455-471
39. Giri D., Ozen M., and Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159 6 (2001) 2159-2165
40. KB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63 1 (2003) 2206-2215
41. Xu C., Shen G., Chen C., Linas C.L.G., and Kong A.-N.T. Suppression of NF-KB and NF-KB-regulated gene expression by sulforaphane and PEITC through IKBa, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24 (2005) 4486-4495
42. Ruparel S.B., Friedrichs W.E., Li X., Talayero B., and Degraffenried L. Role of NF-kB in postate cancer progression. Proc Am Assoc Cancer Res 47 (2006) 5337-5338
43. Dolcet X., Llobet D., Pallares J., and Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 446 5 (2005) 475-482
44. Uzzo R.G., Crispen P.L., Golovine K., Makhov P., Horwitz E.M., and Kolenko V.M. Diverse effects of zinc on NF-kB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis 27 10 (2006) 1980-1990
45. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-KB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
46. Yoshizawa K., Willet W.C., Morris S.J., Stampfer M.J., Spiegelman D., Rimm E.B., and Giovannucci E. A study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90 (1998) 1219-1224
47. Golczewski J.A., and Frenkel G.D. Cellular selenoproteins and the effects of selenite on cell proliferation. Biol Trace Elem Res 20 (1989) 115-126